Next-Generation Regimens. The Future of Hepatitis C Virus Therapy

John Vizuete; Hope Hubbard; Eric Lawitz

doi:10.1016/j.cld.2015.06.009

Next-Generation Regimens. The Future of Hepatitis C Virus Therapy

John Vizuete, Hope Hubbard, Eric Lawitz

Division of Gastroenterology

Research output: Contribution to journal › Article

2 Scopus citations

Abstract

The treatment of chronic hepatitis C virus (HCV) has undergone a period of rapid evolution. The era of combination direct antivirals has led to high rates of sustained viral response (SVR), limited toxicities, and more broad applicability across patient demographics. Even current therapies have their limitations, however, including genotype specificity and variable durations of treatment depending on the presence or absence of cirrhosis. Developing a fixed-duration pangenotypic regimen that can broadly treat all stages of fibrosis with equal rates of SVR in all patients, irrespective of treatment experience, is the goal of future therapies. This article reviews antivirals in development.

Original language	English (US)
Pages (from-to)	707-716
Number of pages	10
Journal	Clinics in Liver Disease
Volume	19
Issue number	4
DOIs	https://doi.org/10.1016/j.cld.2015.06.009
State	Published - Nov 1 2015

Keywords

Direct-acting antivirals
Genotype 1
Hepatitis C
Resistance-associated variants
Second generation

ASJC Scopus subject areas

Hepatology

Access to Document

10.1016/j.cld.2015.06.009

Fingerprint Dive into the research topics of 'Next-Generation Regimens. The Future of Hepatitis C Virus Therapy'. Together they form a unique fingerprint.

Cite this

Vizuete, J., Hubbard, H., & Lawitz, E. (2015). Next-Generation Regimens. The Future of Hepatitis C Virus Therapy. Clinics in Liver Disease, 19(4), 707-716. https://doi.org/10.1016/j.cld.2015.06.009

@article{db45c6707e67422e801bb99ed1e65b39,

title = "Next-Generation Regimens. The Future of Hepatitis C Virus Therapy",

abstract = "The treatment of chronic hepatitis C virus (HCV) has undergone a period of rapid evolution. The era of combination direct antivirals has led to high rates of sustained viral response (SVR), limited toxicities, and more broad applicability across patient demographics. Even current therapies have their limitations, however, including genotype specificity and variable durations of treatment depending on the presence or absence of cirrhosis. Developing a fixed-duration pangenotypic regimen that can broadly treat all stages of fibrosis with equal rates of SVR in all patients, irrespective of treatment experience, is the goal of future therapies. This article reviews antivirals in development.",

keywords = "Direct-acting antivirals, Genotype 1, Hepatitis C, Resistance-associated variants, Second generation",

author = "John Vizuete and Hope Hubbard and Eric Lawitz",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.cld.2015.06.009",

language = "English (US)",

volume = "19",

pages = "707--716",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Next-Generation Regimens. The Future of Hepatitis C Virus Therapy

AU - Vizuete, John

AU - Hubbard, Hope

AU - Lawitz, Eric

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The treatment of chronic hepatitis C virus (HCV) has undergone a period of rapid evolution. The era of combination direct antivirals has led to high rates of sustained viral response (SVR), limited toxicities, and more broad applicability across patient demographics. Even current therapies have their limitations, however, including genotype specificity and variable durations of treatment depending on the presence or absence of cirrhosis. Developing a fixed-duration pangenotypic regimen that can broadly treat all stages of fibrosis with equal rates of SVR in all patients, irrespective of treatment experience, is the goal of future therapies. This article reviews antivirals in development.

AB - The treatment of chronic hepatitis C virus (HCV) has undergone a period of rapid evolution. The era of combination direct antivirals has led to high rates of sustained viral response (SVR), limited toxicities, and more broad applicability across patient demographics. Even current therapies have their limitations, however, including genotype specificity and variable durations of treatment depending on the presence or absence of cirrhosis. Developing a fixed-duration pangenotypic regimen that can broadly treat all stages of fibrosis with equal rates of SVR in all patients, irrespective of treatment experience, is the goal of future therapies. This article reviews antivirals in development.

KW - Direct-acting antivirals

KW - Genotype 1

KW - Hepatitis C

KW - Resistance-associated variants

KW - Second generation

UR - http://www.scopus.com/inward/record.url?scp=84943586630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943586630&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2015.06.009

DO - 10.1016/j.cld.2015.06.009

M3 - Article

C2 - 26466657

AN - SCOPUS:84943586630

VL - 19

SP - 707

EP - 716

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 4

ER -